Inhibitory rTMS in Dystonic Wilson Patients

Status Completed

Clinical Trial Summary

Wilson disease is a genetic disorder resulting in copper accumulation in liver, brain and eye. The neurologic complications include dystonic syndrome, which is a prolonged and excessive muscle activation responsible for abnormal postures. Hand dystonia prevents daily life activities such as writing, which is particularly disabling, since writing is the only mean of communication in these patients with significant slurred speech. Treatment is limited and only partially effective. Low frequency (<or=1Hz) repetitive transcranial magnetic stimulation (rTMS) has shown inhibiting properties when applied over the cortex. Since dystonia has been correlated to hyperactivation of the neurons of the somatosensory cortex (SSC), we hypothesize that one single 20-minute session of 1 Hz rTMS applied on left SSC will improve writing of the right dystonic hand, assessed immediately at the end of the session.

Clinical Trial Description

This study investigates the handwriting performance of an homogeneous cohort of patients with Wilson disease and right handed dystonia, after one single inhibitory repetitive transcranial magnetic stimulation (rTMS). Fifteen patients with focal right hand dystonia will receive randomly either active or sham rTMS (1 Hz) to the left somatosensory cortex (SSC) in one single 20 minutes session. Handwriting performance will be measured immediately after this unique session (Visual analogic scale of subjective discomfort in writing, DPRE and WCRS scales, pen pressure and pen velocity measured on touchpad), compared to scores obtained 24 hours before the session. Three days later, the patient will receive the other session (sham rTMS or active rTMS) and the same parameters will be evaluated. This is a single-center, randomized, crossover, prospective, clinical and double-blind study (the rTMS session is performed by the neurophysiologist, but the patient and the neurologist who will perform the handwriting evaluation are blind to the session). ;

Study Design

Related Conditions & MeSH terms

Movement Disorders
Repetitive Transcranial Magnetic Stimulation
Wilson Disease

Clinical Trial Details

NCT number	NCT01980433
Study type	Interventional
Source	Assistance Publique - Hôpitaux de Paris
Contact
Status	Completed
Phase	N/A
Start date	January 2014
Completion date	July 2015

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT05623644` - Multimodal MR Imaging Study on ET and PD Patients Subjected With MRgFUS Thalamotomy
Active, not recruiting	`NCT03548779` - North Carolina Genomic Evaluation by Next-generation Exome Sequencing, 2	N/A
Completed	`NCT03295786` - Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease	Phase 1/Phase 2
Completed	`NCT03722212` - Early Diagnosis of the GLUT1 Deficiency Syndrome With a Blood Based Test	N/A
Recruiting	`NCT05973929` - Movement Disorders in Multiple Sclerosis Patients
Terminated	`NCT02823158` - Bilateral Pallidal Stimulation in Patients With Advanced Parkinson's Disease-LATESTIM	N/A
Enrolling by invitation	`NCT01210781` - Target Planning for Placement of DBS-electrodes and Follow-up of the Clinical Efficacy of Stimulation
Enrolling by invitation	`NCT00355927` - Sedation During Microelectrode Recordings Before Deep Brain Stimulation for Movement Disorders.	N/A
Completed	`NCT00037167` - Effects of Exercise Poles on Older Adults During Exercise Walking	Phase 1/Phase 2
Recruiting	`NCT04784494` - MST for Parkinson's Disease	N/A
Terminated	`NCT03270189` - Effect of the Visual Information Change in Functional Dystonia	N/A
Recruiting	`NCT04176692` - The Effects of Muscle Characteristics on the Control of Shoulder Complex During Functional Movements
Recruiting	`NCT04061135` - Neurophysiological, Behavioral, and Cognitive Networks in Movement Disorders	N/A
Suspended	`NCT04912115` - Randomized, Double-Blind, Active Placebo-Controlled Study of Ketamine to Treat Levodopa-Induced Dyskinesia	Phase 2
Completed	`NCT00500994` - Neurobiology of Functional Movement Disorder and Non-Epileptic Seizures	Early Phase 1
Completed	`NCT04536987` - Robot Therapy for Rehabilitation of Hand Movement After Stroke	Phase 2
Recruiting	`NCT00001208` - Botulinum Toxin for the Treatment of Involuntary Movement Disorders
Completed	`NCT02392078` - Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System
Completed	`NCT00552474` - Deep Brain Stimulation to Treat Symptoms of Parkinson's Disease	N/A
Not yet recruiting	`NCT05032911` - Sensorimotor Control in People With and Without Neck Pain

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Inhibitory rTMS in Dystonic Wilson Patients — WILSTIM

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms